A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Subjects must fully understand the study, be willing and able to comply with all trial procedures, voluntarily participate in the clinical trial, and provide written informed consent by signing the informed consent form (ICF).
• Subjects must be aged between 18 and 65 years (inclusive) at the time of ICF signing, regardless of gender.
• Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits.
Locations
Other Locations
China
The Peking University People's Hospital, Beijing, Beijng
RECRUITING
Beijing
Contact Information
Primary
xiaojuan Lai
lai_xiaojuan@vcarepharmatech.com
+8615358160458
Time Frame
Start Date: 2026-08-18
Estimated Completion Date: 2028-12-30
Participants
Target number of participants: 120
Treatments
Experimental: VC005 Tablets Low Dose group
Experimental: VC005 Tablets High Dose group
Placebo_comparator: VC005 Tablets placebo group
Related Therapeutic Areas
Sponsors
Leads: Jiangsu vcare pharmaceutical technology co., LTD